Alopecia Areata Market Report 2026

The alopecia areata market size has grown strongly in recent years. It will grow from $3.81 billion in 2025 to $4.11 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising prevalence of alopecia areata globally, limited treatment options historically, increasing demand for dermatology care, growing hospital and specialty clinic infrastructure, traditional herbal and natural remedies adoption.

The alopecia areata market size is expected to see strong growth in the next few years. It will grow to $5.72 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to development of novel immunotherapy drugs, increasing investment in dermatology research, rising preference for personalized hair loss treatments, expansion of homecare and teledermatology services, growing clinical trials for hair regrowth. Major trends in the forecast period include increasing awareness about autoimmune hair disorders, rising adoption of topical and oral therapies, growth in specialized clinics and homecare solutions, advancements in trichoscopy and diagnostic techniques, increasing research in novel hair regrowth treatments.

The rising incidence of alopecia is expected to drive the growth of the alopecia areata market in the coming years. Alopecia refers to the partial or complete loss of hair, typically from the scalp but sometimes affecting other areas of the body. The increasing occurrence of alopecia is primarily attributed to a rise in autoimmune disorders, higher stress levels, genetic predisposition, and environmental factors that disrupt normal hair follicle function. Treatments for alopecia areata help manage this growing burden by targeting immune-mediated follicular inflammation, promoting hair regrowth, and improving patient quality of life through faster-acting and more effective therapeutic options. For instance, in July 2023, according to an article published by the U.S. Department of Health and Human Services, more than 50 million men and 30 million women are estimated to be affected by androgenetic alopecia in the U.S. each year. Therefore, the rising incidence of alopecia is fueling the growth of the alopecia areata market.

Major companies in the alopecia areata market are focusing on innovative drug approvals, such as Janus kinase (JAK) inhibitors, to strengthen their market presence and provide next-generation therapies. JAK inhibitors are a class of medications that block specific enzymes (JAK1/JAK2) involved in the autoimmune process that attacks hair follicles, thereby stimulating hair regrowth in patients with severe alopecia areata. For instance, in June 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, announced that the US Food and Drug Administration (FDA), a federal agency responsible for public health protection, had approved LITFULOTM (ritlecitinib), the first and only treatment for severe alopecia areata approved for patients as young as 12. It is a once-daily oral therapy for alopecia areata, an autoimmune condition for which there were previously no FDA-approved treatments for teenagers and limited options for adults. LITFULO is a kinase inhibitor that blocks Janus kinase 3 (JAK3) and the TEC family of tyrosine kinases.

In March 2023, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Concert Pharmaceuticals for $576 million. This acquisition is intended to expand Sun Pharma’s presence in the Boston biotech cluster and add deuruxolitinib, a late-stage, potentially best-in-class therapy for alopecia areata, to its growing global dermatology portfolio. Concert Pharmaceuticals is a US-based late-stage clinical biopharmaceutical company that develops treatments for alopecia areata.

Major companies operating in the alopecia areata market are Pfizer Inc., Eli Lilly and Company, Incyte Corporation, AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb, GlaxoSmithKline plc, Aclaris Therapeutics Inc., Almirall SA, Lupin Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Dr Reddys Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Arena Pharmaceuticals, AnaptysBio Inc., Viela Bio, Priovant Therapeutics.

North America was the largest region in the alopecia areata market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alopecia areata market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alopecia areata market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the alopecia areata market by increasing costs for imported drugs, diagnostic devices, and hair regrowth treatment equipment. Segments such as medical treatments, trichoscopy devices, and specialized topical formulations are most affected, particularly in regions like North America, Europe, and Asia-Pacific. The tariffs have led to higher treatment costs and supply chain delays. However, they have also encouraged local manufacturing of therapies and diagnostic tools, promoting regional self-reliance and innovation.

The alopecia areata market research report is one of a series of new reports that provides alopecia areata market statistics, including alopecia areata industry global market size, regional shares, competitors with a alopecia areata market share, detailed alopecia areata market segments, market trends and opportunities, and any further data you may need to thrive in the alopecia areata industry. This alopecia areata market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alopecia areata, also called spot baldness, is an autoimmune disorder in which the immune system attacks hair follicles, causing hair loss and patchy bald spots on the scalp, typically about the size of a coin. It is a non-scarring condition that can affect people of all ages and is characterized by the sudden appearance of small, soft, hairless patches.

The main types of alopecia areata include patchy alopecia areata, alopecia totalis, alopecia universalis, diffuse alopecia areata, ophiasis alopecia, and others. Patchy alopecia areata is a form of hair loss marked by small, circular patches on the scalp or other areas of the body. Treatments include medical therapies, natural remedies, and others. Diagnosis can be made through trichoscopy, skin biopsy, and other methods. These treatments can be delivered via oral, topical, parenteral, and other routes, and are used by end-users such as hospitals, specialty clinics, home care, and others.

The alopecia areata market consists of revenues earned by entities by providing combination therapy, topical immunotherapy, photochemotherapy, and aromatherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The alopecia areata market also includes sales of glucocorticoids, vasodilators, immunomodulators, and Janus kinase inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.